Latest Biological Asset Valuation News

Murray Cod Australia Limited reports a profitable FY25 with a significant biomass increase and completes a $17 million capital raise to fund infrastructure and market expansion ahead of a commercial inflection in FY26.

New Zealand King Salmon Investments Limited reported a significant interim loss driven by biological asset valuation pressures and operational costs, while announcing a strategic $8.14 million property purchase.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.